Monoclonal Antibody Research in the Era of COVID-19
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".
Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 3242
Special Issue Editor
Special Issue Information
Dear Colleagues,
A monoclonal antibody is an antibody originating from a unique B cell lineage, binding only to the same epitope with high affinity for its target. Over the years, monoclonal antibodies have been used or heavily investigated for their potential role against many diseases, including bacterial and viral infection and cancer. Likewise, antibody-based therapy alone or in combination with other treatments has been demonstrated to be effective for both the early and late stages of SARS-COV-2 infection in the past three years.
In this Special Issue, we invite reviews, research papers, and clinical trial applications elaborating on mechanisms whereby monoclonal antibodies act directly and indirectly against various SARS-COV-2 variants and developing strategies and technologies for antibody engineering related to COVID-19 to enhance immune protection. additionally, new combinations of multiple monoclonal antibodies targeting different antigens or bispecific antibodies to overcome the viral escape phenomenon are of interest.
Dr. Miaomiao Shi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
